LLY
ELI LILLY & CoCompliant · 97/100
Sector: Healthcare · Industry: Drug Manufacturers - General · Data as of 2026-02-12
Screening standard
The evidence
| Test | Figure | Limit | Source |
|---|---|---|---|
| Passed: Business activityBusiness activity is compliant. | compliant | ||
| Passed: Debt vs. market capinterest-bearing debt / market cap = 3.40% (< 33% limit). | 3.40% | < 33.00% | |
| Passed: Interest income vs. revenueinterest income / total revenue = 0.27% (< 5% limit). | 0.27% | < 5.00% | |
| Passed: Cash & interest-bearing assets vs. market cap(cash + interest-bearing securities) / market cap = 0.86% (< 33% limit). | 0.86% | < 33.00% |
Every number, sourced
Figures read directly from SEC EDGAR XBRL facts. Don't trust us — verify.
| Figure | Value | Source |
|---|---|---|
| Total revenueRevenues | $65.2B | |
| Interest-bearing debtLong term debt | $29.5B | |
| Cash & interest-bearing securities2 components | $7.4B | |
| Interest incomeInvestment income interest | $175.2M | |
| Total assetsAssets | $112.5B | |
| ReceivablesAccounts receivable net current | $17.8B | |
| Shares outstandingEntity common stock shares outstanding | 941.7M shares | |
| Priceyahoo:24mo-trailing-avg | $919.306 |
Price
Values & Controversies
Separate from the shariah verdict above — always.
No flags. This company isn't on the BNC (Boycott National Committee) priority or divestment lists, or any grassroots BDS-supported campaign we line.